WO2001026671A1 - Procedes de traitement au moyen d'inhibiteurs doubles de metalloproteinase-2 matricielle et de metalloproteinase-9 matricielle - Google Patents
Procedes de traitement au moyen d'inhibiteurs doubles de metalloproteinase-2 matricielle et de metalloproteinase-9 matricielle Download PDFInfo
- Publication number
- WO2001026671A1 WO2001026671A1 PCT/US2000/027949 US0027949W WO0126671A1 WO 2001026671 A1 WO2001026671 A1 WO 2001026671A1 US 0027949 W US0027949 W US 0027949W WO 0126671 A1 WO0126671 A1 WO 0126671A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pain
- mmp
- seq
- polypeptide
- post
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
Definitions
- a typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical.
- a variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination.
- a substituted or inserted amino acid residue may or may not be one encoded by the genetic code.
- a variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non- naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.
- the polynucleotide may include the coding sequence for the mature polypeptide or a fragment thereof, by itself; the coding sequence for the mature polypeptide or fragment in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions.
- a marker sequence that facilitates purification of the fused polypeptide can be encoded.
- Polynucleotides of the invention which are identical or sufficiently identical to the nucleotide sequences contained in SEQ ID NO: 1 or 3, may be used as hybridization probes for cDNA and genomic DNA, to isolate full-length cDNAs and genomic clones encoding MMP-2 or MMP-9 polypeptides and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to the MMP-2 and MMP-9 genes.
- hybridization techniques are known to those of skill in the art.
- these nucleotide sequences are at least 95% identical to that of the referent.
- the probes generally will comprise at least 15 nucleotides.
- such probes will have at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will range between 30 and 50 nucleotides.
- host cells can be genetically engineered to inco ⁇ orate expression systems or portions thereof for polynucleotides of the present invention.
- Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis, et al, BASIC
- Human MMP-2 and MMP-9 proteins are responsible for many biological functions, including many pathologies.
- screening methods to identify compounds that stimulate or that inhibit the function the function or level of the polypeptide.
- agonists or antagonists are employed for diseases and disorders including, but not limited to: stroke; hemorrhage; reperfusion injury; cerebral ischemia; cerebral infarction; enhanced or exaggerated sensitivity to pain, such as hyperalgesia, causalgia and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndromes I and II; arthritic pain; sports injury pain; pain related to viral infection, e.g., HIV, post-polio syndrome, and post-he ⁇ etic neuralgia; phantom limb pain; labor pain; cancer pain; post-chemotherapy pain; post-stroke pain; postoperative pain; physiological pain; inflammatory pain; acute inflammatory conditions/visceral pain, e.g., angina, irritable
- Prefened forms of systemic administration of the pharmaceutical compositions include injection, typically by intravenous injection Other injection routes, such as subcutaneous, intramuscular, or intrape ⁇ toneal, can be used Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents.
- penetrants such as bile salts or fusidic acids or other detergents
- oral administration may also be possible
- Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like
- MMP enzyme expression was assayed by SDS-PAGE zymography using gelatin as an MMP substrate.
- gelatin-containing zymograms equal volumes ( 10 ⁇ l) of tissue extracts normalized for protein concentration were subjected to electrophoresis, without boiling or reduction, through a 10% polyacrylamide gel co- polymerized with gelatin (0.5 mg/ml) at 4°C. After electrophoresis was complete, the gel was incubated for 1 hour at 25°C in a 2.5% Triton X-100 solution, washed two times, 20 minutes each, with water and then incubated overnight at 37°C in a 0.05 M Tris-HCI buffer, pH 8.0, containing 5 mM CaCl2.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne un procédé de traitement d'un patient souffrant de douleur ou d'un accident vasculaire cérébral, ledit procédé comprenant une étape qui consiste à administrer au patient une quantité suffisante pour soulager la douleur d'un inhibiteur double de MMP-2 (SEQ ID NO:2) et de MMP-9 (SEQ ID NO:4) d'origine humaine en combinaison avec un support.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15878799P | 1999-10-12 | 1999-10-12 | |
US60/158,787 | 1999-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001026671A1 true WO2001026671A1 (fr) | 2001-04-19 |
Family
ID=22569708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/027949 WO2001026671A1 (fr) | 1999-10-12 | 2000-10-11 | Procedes de traitement au moyen d'inhibiteurs doubles de metalloproteinase-2 matricielle et de metalloproteinase-9 matricielle |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2001026671A1 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001069261A2 (fr) * | 2000-03-15 | 2001-09-20 | Oxford Glycosciences (Uk) Ltd. | Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire |
EP1283823A1 (fr) * | 2000-05-24 | 2003-02-19 | Smithkline Beecham Corporation | Inhibiteurs des mmp-2/mmp-9 |
US7189700B2 (en) | 2003-06-20 | 2007-03-13 | Kimberly-Clark Worldwide, Inc. | Anti-chrondrosarcoma compounds |
EP2262840A2 (fr) * | 2008-03-03 | 2010-12-22 | Dyax Corp. | Protéines de liaison à la métalloprotéinase 9 et à la métalloprotéinase 2 |
CN102618620A (zh) * | 2012-04-11 | 2012-08-01 | 上海健耕医药科技有限公司 | 一种细胞水平筛选金属基质蛋白酶抑制剂的方法 |
US8455205B2 (en) | 2008-03-03 | 2013-06-04 | Dyax Corp. | Metalloproteinase 9 binding proteins |
US8501181B2 (en) | 2007-12-17 | 2013-08-06 | Dyax Corp. | Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins |
US10314909B2 (en) | 2011-10-21 | 2019-06-11 | Dyax Corp. | Combination therapy comprising an MMP-14 binding protein |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4923818A (en) * | 1987-09-04 | 1990-05-08 | Washington University | DNA clone of human type IV collagenase |
WO1998039024A1 (fr) * | 1997-03-03 | 1998-09-11 | Darwin Discovery Limited | Inhibiteurs selectifs de la metalloprotease matricielle presentant des effets secondaires reduits |
US6114159A (en) * | 1994-03-17 | 2000-09-05 | Max-Delbruck-Centrum Fur Molekulare Medizin | DNA sequences for matrix metalloproteases, their production and use |
-
2000
- 2000-10-11 WO PCT/US2000/027949 patent/WO2001026671A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4923818A (en) * | 1987-09-04 | 1990-05-08 | Washington University | DNA clone of human type IV collagenase |
US6114159A (en) * | 1994-03-17 | 2000-09-05 | Max-Delbruck-Centrum Fur Molekulare Medizin | DNA sequences for matrix metalloproteases, their production and use |
WO1998039024A1 (fr) * | 1997-03-03 | 1998-09-11 | Darwin Discovery Limited | Inhibiteurs selectifs de la metalloprotease matricielle presentant des effets secondaires reduits |
Non-Patent Citations (4)
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001069261A2 (fr) * | 2000-03-15 | 2001-09-20 | Oxford Glycosciences (Uk) Ltd. | Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire |
WO2001069261A3 (fr) * | 2000-03-15 | 2002-05-16 | Oxford Glycosciences Uk Ltd | Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire |
EP1283823A1 (fr) * | 2000-05-24 | 2003-02-19 | Smithkline Beecham Corporation | Inhibiteurs des mmp-2/mmp-9 |
EP1283823A4 (fr) * | 2000-05-24 | 2005-07-27 | Smithkline Beecham Corp | Inhibiteurs des mmp-2/mmp-9 |
US7189700B2 (en) | 2003-06-20 | 2007-03-13 | Kimberly-Clark Worldwide, Inc. | Anti-chrondrosarcoma compounds |
US7795225B2 (en) | 2003-06-20 | 2010-09-14 | Kimberly-Clark Worldwide, Inc. | Anti-chrondrosarcoma compounds |
US8501181B2 (en) | 2007-12-17 | 2013-08-06 | Dyax Corp. | Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins |
EP2262840A2 (fr) * | 2008-03-03 | 2010-12-22 | Dyax Corp. | Protéines de liaison à la métalloprotéinase 9 et à la métalloprotéinase 2 |
EP2262840A4 (fr) * | 2008-03-03 | 2012-08-08 | Dyax Corp | Protéines de liaison à la métalloprotéinase 9 et à la métalloprotéinase 2 |
US8455205B2 (en) | 2008-03-03 | 2013-06-04 | Dyax Corp. | Metalloproteinase 9 binding proteins |
US10314909B2 (en) | 2011-10-21 | 2019-06-11 | Dyax Corp. | Combination therapy comprising an MMP-14 binding protein |
CN102618620A (zh) * | 2012-04-11 | 2012-08-01 | 上海健耕医药科技有限公司 | 一种细胞水平筛选金属基质蛋白酶抑制剂的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6870030B2 (en) | Asp2 | |
JPH11279196A (ja) | Vanilrep1ポリペプチドおよびvanilrep1ポリヌクレオチ ド | |
US20020107195A1 (en) | Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha | |
JP2006325596A (ja) | シアロアドヘシンファミリーメンバー−2(saf−2) | |
US20020028485A1 (en) | Novel compounds | |
KR20010041418A (ko) | 프로테아제-활성화되는 수용체 4 및 그것의 사용 | |
WO2001026671A1 (fr) | Procedes de traitement au moyen d'inhibiteurs doubles de metalloproteinase-2 matricielle et de metalloproteinase-9 matricielle | |
JP2003526674A (ja) | ボンベシン受容体3の使用 | |
US20040033943A1 (en) | Hcn polypeptides and polynucleotides and their use in therapy | |
JP2002523029A (ja) | ヒトヒストンデアセチラーゼ遺伝子hd4 | |
EP0861898A1 (fr) | Polynucleotide et séquence de polypeptide la Cathepsine-K du rat | |
US6274717B1 (en) | Splicing variant of human membrane-type matrix metalloproteinease-5 (MT-MMP5-L) | |
JPH10295387A (ja) | 新規g−タンパク質結合性7tmレセプターのクローニング | |
US5879908A (en) | CRFG-1a, a target and marker for chronic renal failure | |
JP2002526098A (ja) | 新規なぺプチド類 | |
US6359116B1 (en) | Compounds | |
EP0908515A2 (fr) | Polypeptide pancréatique | |
US6187560B1 (en) | Polynucleotides and polypeptides belonging to the uncoupling proteins family | |
EP0892053A2 (fr) | Production de polypeptide HPMBQ91 recombinant et ses utilisations | |
US20040198649A1 (en) | Human vanilloid receptor gene | |
EP0869178A1 (fr) | SAF-3, un membre de la famille des sialoadhésines | |
JP2001500386A (ja) | インテグリンリガンドであるヒトMindin | |
JP2002527037A (ja) | サイトカインファミリーメンバーef−7 | |
EP1187627B1 (fr) | Utilisations de polypeptides et polynucleotides h-trek-1 | |
US20020004492A1 (en) | New use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |